-
1
-
-
0018974089
-
The development and use of radiolabeled antitumor antibodies
-
Presman D. The development and use of radiolabeled antitumor antibodies. Cancer Res 1980;40:2960
-
(1980)
Cancer Res
, vol.40
, pp. 2960
-
-
Presman, D.1
-
2
-
-
77949895194
-
Preclinical and clinical studies of peptide receptor radionuclide therapy
-
Pool SE, Krenning EP, Koning GA, et al. Preclinical and clinical studies of peptide receptor radionuclide therapy. Semin Nucl Med 2010;40:209
-
(2010)
Semin Nucl Med
, vol.40
, pp. 209
-
-
Pool, S.E.1
Krenning, E.P.2
Koning, G.A.3
-
3
-
-
69449106959
-
Peptide-receptor radionuclide therapy for endocrine tumors
-
van Essen M, Krenning EP, Kam BL, et al. Peptide-receptor radionuclide therapy for endocrine tumors. Nat Rev Endocrinol 2009;5:382
-
(2009)
Nat Rev Endocrinol
, vol.5
, pp. 382
-
-
Van Essen, M.1
Krenning, E.P.2
Kam, B.L.3
-
5
-
-
0031911476
-
Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: Present status, future prospects and limitations
-
Behr TM, Goldenberg DM, Becker W. Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: Present status, future prospects and limitations. Eur J Nucl Med 1998;25:201
-
(1998)
Eur J Nucl Med
, vol.25
, pp. 201
-
-
Behr, T.M.1
Goldenberg, D.M.2
Becker, W.3
-
6
-
-
14844358655
-
Long-term followup of renal function after peptide receptor radiation therapy with 90Y-DOTA0,Tyr3-Octreotide and 177Lu-DOTA0,Tyr3- Octreotate
-
Valkema R, Pauwels SA, Kvols LK, et al. Long-term followup of renal function after peptide receptor radiation therapy with 90Y-DOTA0,Tyr3-Octreotide and 177Lu-DOTA0,Tyr3- Octreotate. J Nucl Med 2005;46:83S.
-
(2005)
J Nucl Med
, vol.46
-
-
Valkema, R.1
Pauwels, S.A.2
Kvols, L.K.3
-
7
-
-
0036843101
-
Megalin and cubilin-the story of two multipurpose receptors unfold
-
Verroust PJ, Christensen EI. Megalin and cubilin-the story of two multipurpose receptors unfold. Nephrol Dial Transplant 2002;17:1867
-
(2002)
Nephrol Dial Transplant
, vol.17
, pp. 1867
-
-
Verroust, P.J.1
Christensen, E.I.2
-
8
-
-
33644665426
-
Megalin Is Essential for Renal Proximal Tubule Reabsorption of 111In-DTPAOctreotide
-
de Jong M, Barone R, Krenning E, et al. Megalin Is Essential for Renal Proximal Tubule Reabsorption of 111In-DTPAOctreotide. J Nucl Med 2005;46:1696
-
(2005)
J Nucl Med
, vol.46
, pp. 1696
-
-
De Jong, M.1
Barone, R.2
Krenning, E.3
-
9
-
-
77949273386
-
Albumin-derived peptides efficiently reduce renal uptake of radiolabelled peptides
-
Vegt E, Eek A, Oyen WJ, et al. Albumin-derived peptides efficiently reduce renal uptake of radiolabelled peptides. Eur J Nucl Med Mol Imaging 2010;37:226
-
(2010)
Eur J Nucl Med Mol Imaging
, vol.37
, pp. 226
-
-
Vegt, E.1
Eek, A.2
Oyen, W.J.3
-
10
-
-
25144519114
-
Localisation and mechanism of renal retention of radiolabelled somatostatin analogues
-
Melis M, Krenning EP, Bernard BF, et al. Localisation and mechanism of renal retention of radiolabelled somatostatin analogues. Eur J Nucl Med Mol Imaging 2005;32:1136
-
(2005)
Eur J Nucl Med Mol Imaging
, vol.32
, pp. 1136
-
-
Melis, M.1
Krenning, E.P.2
Bernard, B.F.3
-
11
-
-
79953708503
-
Renal uptake of different radiolabelled peptides is mediated by megalin: SPECT and biodistribution studies in megalin-deficient mice
-
Vegt E, Melis M, Eek A, et al. Renal uptake of different radiolabelled peptides is mediated by megalin: SPECT and biodistribution studies in megalin-deficient mice. Eur J Nucl Med Mol Imaging 2011;38:623
-
(2011)
Eur J Nucl Med Mol Imaging
, vol.38
, pp. 623
-
-
Vegt, E.1
Melis, M.2
Eek, A.3
-
12
-
-
77954966119
-
Renal toxicity of radiolabeled peptides and antibody fragments: Mechanisms, impact on radionuclide therapy, and strategies for prevention
-
Vegt E, de Jong M, Wetzels JFM, et al. Renal toxicity of radiolabeled peptides and antibody fragments: Mechanisms, impact on radionuclide therapy, and strategies for prevention. J Nucl Med 2010;51:1049
-
(2010)
J Nucl Med
, vol.51
, pp. 1049
-
-
Vegt, E.1
De Jong, M.2
Wetzels, J.F.M.3
-
13
-
-
34248549130
-
Indication for different mechanisms of kidney uptake of radiolabeled peptides
-
Gotthardt M, van Eerd-Vismale J, Oyen WJ, et al. Indication for different mechanisms of kidney uptake of radiolabeled peptides. J Nucl Med 2007;48:596
-
(2007)
J Nucl Med
, vol.48
, pp. 596
-
-
Gotthardt, M.1
Van Eerd-Vismale, J.2
Oyen, W.J.3
-
14
-
-
43549101411
-
Alternative binding proteins: Affibody binding proteins developed from a small three-helix bundle scaffold
-
Nygren PA. Alternative binding proteins: Affibody binding proteins developed from a small three-helix bundle scaffold. FEBS J 2008;275:2668
-
(2008)
FEBS J
, vol.275
, pp. 2668
-
-
Nygren, P.A.1
-
15
-
-
77953130101
-
Affibody molecules: Engineered proteins for therapeutic, diagnostic and biotechnological applications
-
Löfblom J, Feldwisch J, Tolmachev V, et al. Affibody molecules: Engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett 2010;584:2670
-
(2010)
FEBS Lett
, vol.584
, pp. 2670
-
-
Löfblom, J.1
Feldwisch, J.2
Tolmachev, V.3
-
16
-
-
79952118497
-
Radionuclide molecular imaging using Affibody molecules
-
Ahlgren S, Tolmachev V. Radionuclide molecular imaging using Affibody molecules. Curr Pharm Biotechnol 2010;11:581
-
(2010)
Curr Pharm Biotechnol
, vol.11
, pp. 581
-
-
Ahlgren, S.1
Tolmachev, V.2
-
17
-
-
77953927395
-
Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules
-
Baum RP, Prasad V, Müller D, et al. Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules. J Nucl Med 2010;51:892
-
(2010)
J Nucl Med
, vol.51
, pp. 892
-
-
Baum, R.P.1
Prasad, V.2
Müller, D.3
-
18
-
-
33947672248
-
Radionuclide therapy of HER2-positive microxenografts using a 177Lulabeled HER2-specific Affibody molecule
-
Tolmachev V, Orlova A, Pehrson R, et al. Radionuclide therapy of HER2-positive microxenografts using a 177Lulabeled HER2-specific Affibody molecule. Cancer Res 2007; 67:2773
-
(2007)
Cancer Res
, vol.67
, pp. 2773
-
-
Tolmachev, V.1
Orlova, A.2
Pehrson, R.3
-
19
-
-
58149305658
-
Development and preclinical characterisation of 99mTc-labelled Affibody molecules with reduced renal uptake
-
Ekblad T, Tran T, Orlova A, et al. Development and preclinical characterisation of 99mTc-labelled Affibody molecules with reduced renal uptake. Eur J Nucl Med Mol Imaging 2008;35:2245
-
(2008)
Eur J Nucl Med Mol Imaging
, vol.35
, pp. 2245
-
-
Ekblad, T.1
Tran, T.2
Orlova, A.3
-
20
-
-
77949268342
-
Re-maSGS-Z (HER2:342), a potential Affibody conjugate for systemic therapy of HER2-expressing tumours
-
Orlova A, Tran TA, Ekblad T, et al. (186)Re-maSGS-Z (HER2:342), a potential Affibody conjugate for systemic therapy of HER2-expressing tumours. Eur J Nucl Med Mol Imaging 2010;37:260
-
(2010)
Eur J Nucl Med Mol Imaging
, vol.37
, pp. 260
-
-
Orlova, A.1
Tran, T.A.2
Ekblad, T.3
-
21
-
-
79952798198
-
Molecular design and optimization of 99mTc-labeled recombinant affibody molecules improves their biodistribution and imaging properties
-
Wallberg H, Orlova A, Altai M, et al. Molecular design and optimization of 99mTc-labeled recombinant affibody molecules improves their biodistribution and imaging properties. J Nucl Med 2011;52:461
-
(2011)
J Nucl Med
, vol.52
, pp. 461
-
-
Wallberg, H.1
Orlova, A.2
Altai, M.3
-
22
-
-
38949103710
-
Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant affibody molecules
-
Ahlgren S, Orlova A, Rosik D, et al. Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant affibody molecules. Bioconjug Chem 2008;19:235
-
(2008)
Bioconjug Chem
, vol.19
, pp. 235
-
-
Ahlgren, S.1
Orlova, A.2
Rosik, D.3
-
23
-
-
66149150263
-
Targeting of HER2- expressing tumors using a site-specifically 99mTc-labeled recombinant Affibody molecule ZHER2:2395 with C-terminal engineered cysteine
-
Ahlgren S, Wallberg H, Tran TA, et al. Targeting of HER2- expressing tumors using a site-specifically 99mTc-labeled recombinant Affibody molecule ZHER2:2395 with C-terminal engineered cysteine. J Nucl Med 2009;50:781
-
(2009)
J Nucl Med
, vol.50
, pp. 781
-
-
Ahlgren, S.1
Wallberg, H.2
Tran, T.A.3
-
24
-
-
58149083156
-
Effects of lysine-containing mercaptoacetyl-based chelators on the biodistribution of 99mTc-labeled anti-HER2 Affibody molecules
-
Tran T, Ekblad T, Orlova A, et al. Effects of lysine-containing mercaptoacetyl-based chelators on the biodistribution of 99mTc-labeled anti-HER2 Affibody molecules. Bioconjugate Chem 2008;19:2568
-
(2008)
Bioconjugate Chem
, vol.19
, pp. 2568
-
-
Tran, T.1
Ekblad, T.2
Orlova, A.3
-
25
-
-
33646261864
-
Tumor imaging a using picomolar affinity HER2 binding Affibody molecule
-
Orlova A, Magnusson M, Eriksson T, et al. Tumor imaging a using picomolar affinity HER2 binding Affibody molecule. Cancer Res 2006;66:4339
-
(2006)
Cancer Res
, vol.66
, pp. 4339
-
-
Orlova, A.1
Magnusson, M.2
Eriksson, T.3
-
26
-
-
20844462100
-
Endocytosis of the somatostatin analogue, octreotide, by the proximal tubule-derived opossum kidney (OK) cell line
-
Barone R, van der Smissen P, Devuyst O, et al. Endocytosis of the somatostatin analogue, octreotide, by the proximal tubule-derived opossum kidney (OK) cell line. Kidney Int 2005;67:969
-
(2005)
Kidney Int
, vol.67
, pp. 969
-
-
Barone, R.1
Van Der Smissen, P.2
Devuyst, O.3
-
27
-
-
0142243132
-
Transforming growth factor-b1 reduces megalin- and cubilin-mediated endocytosis of albumin in proximal-tubule-derived opossum kidney cells
-
Gekle M, Knaus P, Nielsen R, et al. Transforming growth factor-b1 reduces megalin- and cubilin-mediated endocytosis of albumin in proximal-tubule-derived opossum kidney cells. J Physiol 2003;552:471
-
(2003)
J Physiol
, vol.552
, pp. 471
-
-
Gekle, M.1
Knaus, P.2
Nielsen, R.3
-
28
-
-
49049114956
-
Comparison of 111In- DOTA-NOC and 111In-DOTA-TATE distribution in the target and dose-limiting tissues: Conflicting results in vitro and in vivo
-
Cihlo J, Melicharová L, Petrik M, et al. Comparison of 111In- DOTA-NOC and 111In-DOTA-TATE distribution in the target and dose-limiting tissues: Conflicting results in vitro and in vivo. Anticancer Res 2008;28:2189
-
(2008)
Anticancer Res
, vol.28
, pp. 2189
-
-
Cihlo, J.1
Melicharová, L.2
Petrik, M.3
-
29
-
-
77953872478
-
Kit formulation for 99mTc-labeling of recombinant anti-HER2 Affibody molecules with a C-terminally engineered cysteine
-
Ahlgren S, Andersson K, Tolmachev V. Kit formulation for 99mTc-labeling of recombinant anti-HER2 Affibody molecules with a C-terminally engineered cysteine. Nucl Med Biol 2010;37:539
-
(2010)
Nucl Med Biol
, vol.37
, pp. 539
-
-
Ahlgren, S.1
Andersson, K.2
Tolmachev, V.3
-
30
-
-
0032857025
-
Megalin knockout mice as an animal model of low molecular weight proteinuria
-
Leheste JR, Rolinski B, Vorum H, et al. Megalin knockout mice as an animal model of low molecular weight proteinuria. Am J Pathol 1999;155:136
-
(1999)
Am J Pathol
, vol.155
, pp. 136
-
-
Leheste, J.R.1
Rolinski, B.2
Vorum, H.3
-
31
-
-
50249085637
-
Slow Internalization Of Anti-HER2 Synthetic Affibody Monomer 111In-DOTA-ZHER2:342-pep2: Implications For Development Of Labeled Tracers
-
Wallberg H, Orlova A. Slow internalization of anti-HER2 synthetic affibody monomer 111In-DOTA-ZHER2:342-pep2: Implications for development of labeled tracers. Cancer Biother Radiopharm 2008;23:435
-
(2008)
Cancer Biother Radiopharm
, vol.23
, pp. 435
-
-
Wallberg, H.1
Orlova, A.2
-
32
-
-
0034073250
-
Cubilin is an albumin binding protein important for renal tubular albumin reabsorption
-
Birn H, Fyfe JC, Jacobsen C, et al. Cubilin is an albumin binding protein important for renal tubular albumin reabsorption. J Clin Invest 2000;105:1353
-
(2000)
J Clin Invest
, vol.105
, pp. 1353
-
-
Birn, H.1
Fyfe, J.C.2
Jacobsen, C.3
-
33
-
-
0030140103
-
Reduction of renal uptake of monoclonal antibody fragments by amino acid infusion
-
Behr TM, Becker WS, Sharkey RM, et al. Reduction of renal uptake of monoclonal antibody fragments by amino acid infusion. J Nucl Med 1996;37:829
-
(1996)
J Nucl Med
, vol.37
, pp. 829
-
-
Behr, T.M.1
Becker, W.S.2
Sharkey, R.M.3
-
34
-
-
0029738947
-
Inhibition of renal uptake of indium-111-DTPA-octreotide in vivo
-
de Jong M, Rolleman EJ, Bernard BF, et al. Inhibition of renal uptake of indium-111-DTPA-octreotide in vivo. J Nucl Med 1996;37:1388
-
(1996)
J Nucl Med
, vol.37
, pp. 1388
-
-
De Jong, M.1
Rolleman, E.J.2
Bernard, B.F.3
-
35
-
-
79954991349
-
Localization, mechanism and reduction of renal retention of technetium- 99m labeled epidermal growth factor receptor-specific nanobody in mice
-
Gainkam LO, Caveliers V, Devoogdt N, et al. Localization, mechanism and reduction of renal retention of technetium- 99m labeled epidermal growth factor receptor-specific nanobody in mice. Contrast Media Mol Imaging 2011;6:85
-
(2011)
Contrast Media Mol Imaging
, vol.6
, pp. 85
-
-
Gainkam, L.O.1
Caveliers, V.2
Devoogdt, N.3
-
36
-
-
57449108683
-
Epidermal growth factor receptor signaling in the kidney Key roles in physiology and disease
-
Melenhorst WBWH, Mulder GM, Xi Q, et al. Epidermal growth factor receptor signaling in the kidney. Key roles in physiology and disease. Hypertension 2008;52:987
-
(2008)
Hypertension
, vol.52
, pp. 987
-
-
Melenhorst, W.B.W.H.1
Mulder, G.M.2
Xi, Q.3
-
37
-
-
33947193534
-
Synthetic Affibody molecules: A novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors
-
Orlova A, Tolmachev V, Pehrson R, et al. Synthetic Affibody molecules: A novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors. Cancer Res 2007;67:2178
-
(2007)
Cancer Res
, vol.67
, pp. 2178
-
-
Orlova, A.1
Tolmachev, V.2
Pehrson, R.3
-
38
-
-
79953275504
-
Imaging agents for in vivo molecular profiling of disseminated prostate cancer cellular processing of 111in-labeled chx-a¢¢-dtpatrastuzumab and anti-her2 aby-025 affibody molecule by prostate cancer cell lines
-
Malmberg J, Tolmachev V, Orlova A. Imaging agents for in vivo molecular profiling of disseminated prostate cancer. Cellular processing of 111In-labeled CHX-A¢¢-DTPAtrastuzumab and anti-HER2 ABY-025 Affibody molecule by prostate cancer cell lines. Exp Ther Med 2011;2:523
-
(2011)
Exp Ther Med
, vol.2
, pp. 523
-
-
Malmberg, J.1
Tolmachev, V.2
Orlova, A.3
-
39
-
-
72149106173
-
Design, synthesis and biological evaluation of a multifunctional HER2 specific Affibody molecule for molecular imaging
-
Tran TA, Rosik D, Abrahmse'n L, et al. Design, synthesis and biological evaluation of a multifunctional HER2 specific Affibody molecule for molecular imaging; Eur J Nucl Med Mol Imaging 2009;36:1864
-
(2009)
Eur J Nucl Med Mol Imaging
, vol.36
, pp. 1864
-
-
Tran, T.A.1
Rosik, D.2
Abrahmse'n, L.3
-
40
-
-
84862763098
-
Order of amino acids in C-terminal cysteine-containing peptide-based chelators influences biodistribution of 99mTc-labeled recombinant Affibody molecules
-
Altai M, Wallberg H, Orlova A, et al. Order of amino acids in C-terminal cysteine-containing peptide-based chelators influences biodistribution of 99mTc-labeled recombinant Affibody molecules. Amino Acids 2012;42:1975
-
(2012)
Amino Acids
, pp. 42
-
-
Altai, M.1
Wallberg, H.2
Orlova, A.3
-
41
-
-
33646739287
-
Effects of HER2-binding affibody molecules on intracellular signaling pathways
-
Ekerljung L, Steffen AC, Carlsson J, Lennartsson J. Effects of HER2-binding affibody molecules on intracellular signaling pathways. Tumour Biol 2006;27:201
-
(2006)
Tumour Biol
, vol.27
, pp. 201
-
-
Ekerljung, L.1
Steffen, A.C.2
Carlsson, J.3
Lennartsson, J.4
|